Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Pharmacologic Prevention Of Post-ERCP Pancreatitis: Is Nitroglycerin A Sangreal?
V. Muralidharan, P. Jamidar
Published 2006 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
This paper references
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
G. Cavallini (1996)
Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis.
P. Mosler (2005)
Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and patients with biliary dyskinesia.
M. Guelrud (1988)
Effects of botulinum toxin A on the sphincter of Oddi: an in vivo and in vitro study
J. A. Sand (1998)
Gabexate mesilate for the prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography.
G. Cavallini (1996)
Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction.
P. Pasricha (1994)
The secret (GTN) of successful ERCP cannulation: a prospective randomised controlled study.
A. Ghori (2002)
Mechanical prevention of post-ERCP pancreatitis by pancreatic stents: results, techniques, and indications.
P. Tarnasky (2003)
3346 Evaluation of recombinant human plateletactivating factor acetylhydrolase (rpaf-ah) for reducing the incidence and severity of post-ercp acute pancreatitis (ap).
S. Sherman (2000)
A comparison of nonionic versus ionic contrast media: results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group.
G. K. Johnson (1995)
Sincalide: a cholecystokinin agonist as an aid in endoscopic retrograde cholangiopancreatography--a prospective assessment.
A. Weston (1997)
Topical application of nitrates onto the papilla of Vater: manometric and clinical results.
T. Wehrmann (2001)
A randomized double-blind trial of cholecystokinin during ERCP.
J. Thompson (1986)
Efficacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, cross over trial.
M. Khuroo (1992)
Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP?
T. Rabenstein (2002)
Endoscopic sphincterotomy complications and their management: an attempt at consensus.
P. Cotton (1991)
Efficacy of Recombinant Human Interleukin-10 in Prevention of Acute Pancreatitis After ERCP in Subjects with Increased Risk: Randomized Prospective Multicenter Study
S. Sherman (2005)
Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
S. Sherman (2003)
Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis.
T. Rabenstein (2004)
Use of corticosteroids in the prevention of post-ERCP pancreatitis: results of a controlled prospective study
G. D. Palma (1999)
Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction.
T. Wehrmann (1998)
A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.
A. Kaffes (2006)
Endoscopic removal of common bile duct stones through the intact papilla after medical sphincter dilation.
M. Staritz (1985)
Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent.
S. Sherman (1994)
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
B. Murray (2003)
Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction
T. Wehrmann (2000)
Complications of endoscopic biliary sphincterotomy.
M. Freeman (1996)
Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial.
M. Moretó (2003)
Prospective randomized double‐blind placebo‐controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography‐induced pancreatitis
S. Sudhindran (2001)
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
A. Andriulli (2000)
A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis.
A. Budzyńska (2001)
This paper is referenced by
The value of transdermal Glyceryl Trinitrate in the prevention of post-ERCP pancreatitis in comparison to Octreotide and Diclofenac injection.
E. Nashaat (2010)
Endoscopic Retrograde Cholangiopancreatography and Endoscopic Ultrasound
J. Meenan (2008)
Pharmacological approach to acute pancreatitis.
U. Bang (2008)
Protocol‐based management strategy for post‐endoscopic retrograde cholangiopancreatography pancreatitis: Can it make a difference?
D. Bhasin (2008)
Meta‐analysis: nitroglycerin for prevention of post‐ERCP pancreatitis
U. Bang (2009)
Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography.
J. Lieb (2007)
Comparative study between transdermal Glyceryl Trinitrate, Octreotide, and Diclofenac injection in the prevention of post-ERCP pancreatitis
E. Nashaat (2010)
Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by pancreatic duct stenting: should it be routine?
R. Kozarek (2011)